PSTA-2413

**PSTA-2413** is an investigational oral small molecule developed by Prospect Therapeutics as a pan-RAS inhibitor with selectivity for mutant over wild-type KRAS. It disrupts the RAS/BRAF interaction by forming a tri-complex with RAS(ON) and cyclophilin A (CypA), demonstrating nanomolar potency in vitro against various RAS mutants, activity in AMG510-resistant cells, and robust in vivo antitumor efficacy with tumor regression in preclinical models of colorectal cancer, non-small cell lung cancer, and other solid tumors. The compound exhibits favorable pharmacokinetics, a 10-fold safety margin in rat toxicity studies, and advantages over competitors like RMC-6236 and ERAS-0015 in potency and wild-type selectivity, positioning it as a potential best-in-class candidate for RAS-driven cancers.[1][3][5]